Table 2.

Cause-specific incidence of death and graft failure and hazards ratios for HCV positivity in the PS-matched cohort

	HCV+		HCV−		Comparisonb
	No. of events	Incidence ratea	No. of events	Incidence ratea	HR (95% CI)	P
Recipient death
Cardiovascular disease	66	0.9	51	0.64	1.40 (0.97–2.02)	0.07
Infection	62	0.85	40	0.5	1.64 (1.12–2.42)	0.01
Malignancy	53	0.72	38	0.48	1.54 (1.01–2.36)	0.05
Graft failure	5	0.07	5	0.06	1.10 (0.31–3.84)	0.88
Liver failure	17	0.23
Others	60	0.82	66	0.83	0.99 (0.70–1.39)	0.95
Unknown	104	1.42	99	1.24	1.17 (0.89–1.53)	0.25
Graft failure
Chronic rejection	143	2.03	127	1.65	1.25 (0.99–1.59)	0.06
Acute rejection	55	0.78	51	0.66	1.17 (0.80–1.70)	0.42
Primary failure	31	0.44	37	0.48	0.88 (0.54–1.41)	0.59
Recurrent disease	27	0.38	15	0.19	2.00 (1.06–3.78)	0.03
BK virus	14	0.2	14	0.18	1.08 (0.51–2.25)	0.85
Infection	18	0.26	11	0.14	1.77 (0.84–3.74)	0.13
Graft thrombosis	14	0.2	21	0.27	0.68 (0.35–1.31)	0.24
Non-compliance	17	0.24	13	0.17	1.40 (0.68–2.88)	0.37
Glomerular pathologyb	9	0.13	8	0.1	1.24 (0.47–3.24)	0.66
Others	25	0.35	20	0.26	1.33 (0.73–2.42)	0.35
Unknown	23	0.33	16	0.21	1.60 (0.84–3.04)	0.15

^arate per 100 patient per year.

^bde novo glomerular pathology which is different from the primary kidney disease.